Small Fiber Neuropathy
Clinical guidelines for managing sensory and autonomic small-fiber neuropathies, evaluating intraepidermal nerve fiber density, QSART diagnostics, and reviewing gabapentinoid and sodium channel therapies.
🧠 Standard of Care & Symptoms
Small Fiber Neuropathy (SFN) is a peripheral neuropathy characterized by selective damage to small, thinly myelinated A-delta and unmyelinated C nerve fibers. It is primarily characterized by severe neuropathic pain and autonomic dysfunction.
- Presentation: Key clinical features.
- *Burning & Tingling Pain:* Classically starts in the soles of the feet and spreads proximally in a length-dependent, symmetrical "stocking-glove" pattern. Described as burning, shooting, icy, or like "walking on glass."
- *Allodynia & Hyperalgesia:* Extreme sensitivity where normally non-painful stimuli (such as bedsheets or light touch) trigger severe pain.
- *Autonomic Dysfunction:* Occurs when autonomic small fibers are damaged, leading to orthostatic intolerance (dizziness upon standing), gastroparesis, chronic constipation/diarrhea, abnormal sweating patterns (anhidrosis or hyperhidrosis), and dry eyes/mouth.
- *Normal Reflexes & Strength:* SFN spares large myelinated fibers, meaning motor strength, coordination, and deep tendon reflexes (like the knee jerk) remain completely normal on examination.
🧬 Diagnostics & Fiber Pathophysiology
Diagnosis requires a skin biopsy to count intraepidermal fibers, autonomic function testing, and normal large-fiber electrodiagnostics to rule out alternative neuropathies.
- Diagnostic Markers: Key criteria.
- Skin Punch Biopsy (IENFD Analysis): The gold standard diagnostic test. A 3-mm punch biopsy is taken from the distal leg (10 cm above the lateral malleolus) and proximal thigh. Histopathology uses immunostaining against **PGP 9.5** to visualize and count individual nerve fibers. A reduction in **Intraepidermal Nerve Fiber Density (IENFD)** below age- and sex-adjusted norms confirms SFN.
- Quantitative Sudomotor Axon Reflex Test (QSART): Measures sweat output in response to acetylcholine stimulation, evaluating the integrity of postganglionic sympathetic sudomotor small fibers.
- Normal Electromyography & Nerve Conduction Studies (EMG/NCS): Routine NCS only evaluates large myelinated fibers. A normal EMG/NCS in a patient with burning pain is a key diagnostic pointer, ruling out large-fiber neuropathies.
Pathophysiology of Small Fiber Loss
The pain and autonomic symptoms in SFN stem from the selective degeneration of specific peripheral nerve fibers:
- A-Delta and C Fiber Targets: Small fibers comprise thinly myelinated **A-delta fibers** (transmitting cold and fast pain signals) and unmyelinated **C fibers** (transmitting warm temperature, slow burning pain, and autonomic signals).
- Sodium Channel Hyperexcitability: Genetic subtypes of SFN are driven by gain-of-function mutations in **SCN9A** (encoding the **Nav1.7** sodium channel) or **SCN10A** (encoding **Nav1.8**). These mutations render nociceptive small-fiber neurons hyperexcitable, causing them to fire spontaneously and continuously, manifesting as severe neuropathic pain.
- Etiological Triggers: Small fiber loss is commonly triggered by impaired glucose metabolism (diabetes/pre-diabetes), autoimmune diseases (**Sjögren's Syndrome**, Systemic Lupus Erythematosus, sarcoidosis), paraproteinemia, or direct toxic damage (alcoholism, chemotherapy).
💊 Neuropathic Pain & Immune Management
Treatment focuses on managing chronic pain symptoms, supporting autonomic function, and treating any identified underlying cause.
First-Line Symptomatic Pharmacotherapy
- Gabapentinoids: Oral **Pregabalin** (150-600 mg daily) or **Gabapentin** (900-3600 mg daily) are first-line agents. They bind to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release and dampening nerve pain.
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): **Duloxetine** (30-60 mg daily) is highly effective, promoting descending inhibitory pain pathways in the spinal cord.
- Tricyclic Antidepressants (TCAs): Low-dose **Amitriptyline** or **Nortriptyline** (10-75 mg at bedtime) is deployed, acting via sodium channel blockade and monoamine reuptake inhibition.
Disease-Modifying & Autonomic Therapies
- Immunomodulatory Therapy: In patients with confirmed autoimmune-mediated SFN (e.g. secondary to Sjögren's or sarcoidosis), **Intravenous Immunoglobulin (IVIG)** therapy can halt small-fiber degeneration and promote fiber regeneration.
- Glycemic Control: In diabetic or pre-diabetic SFN, strict dietary changes and glucose control are the only proven measures to encourage epidermal nerve fiber regeneration.
🔬 Active Clinical Trials
Clinical trials are currently investigating selective Nav1.7 sodium channel blockers, IVIG for idiopathic SFN, and novel topical agents.
Evaluating the efficacy of VX-548, an oral, highly selective blocker of the Nav1.8 sodium channel. Because Nav1.8 is restricted to peripheral nociceptive neurons, this agent aims to block pain signaling without causing central side effects.
Key Inclusion: Age 18 to 75, biopsy-proven SFN, and average daily pain score ≥ 4 on the Numerical Rating Scale.A randomized, double-blind, placebo-controlled trial evaluating if monthly IVIG infusions improve pain and increase intraepidermal nerve fiber density in patients with suspected autoimmune-mediated SFN.
Key Inclusion: Age 18 to 70, confirmed SFN via skin biopsy, positive serum autoimmune markers, and failed at least two standard pain medications.Evaluating if daily application of a high-concentration topical cannabinoid formulation directly to the feet reduces localized allodynia and burning sensations.
Key Inclusion: Age ≥ 18, probable SFN, and severe burning pain localized strictly to the feet.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Small Fiber Neuropathy, establish these clinical care pathways:
- Perform a 3-mm Skin Punch Biopsy: If not yet completed, get an IENFD skin biopsy to obtain objective, baseline quantification of your small fiber density.
- Work-Up for Underlying Causes: Ensure your physician runs a complete screening panel, including an oral glucose tolerance test (OGTT), Sjögren's antibodies (SSA/SSB), serum protein electrophoresis (SPEP), and immunofixation.
- Optimize Neuropathic Pain Regimen: Work with a neurologist or pain specialist to titrate Gabapentinoids, SNRIs, or topical therapies to achieve acceptable pain control.
- Assess Autonomic Functions: If experiencing lightheadedness or digestive issues, schedule a QSART or tilt-table test to evaluate autonomic fiber involvement.
❓ Patient FAQ
Q: Why did my EMG and nerve conduction studies (NCS) come back completely normal if I have severe nerve pain?
A: Standard EMG and NCS only evaluate large, myelinated nerve fibers (which control motor strength and vibration/touch sensation). Small Fiber Neuropathy exclusively damages tiny, unmyelinated fibers that are too small to be detected by standard NCS. A normal EMG/NCS actually helps confirm SFN by ruling out large-fiber damage.
Q: Can small nerve fibers grow back?
A: Yes. Unlike large fibers, small epidermal nerve fibers have the capacity to regenerate. If the underlying cause is successfully treated (such as reversing pre-diabetes through diet/exercise or controlling inflammation in autoimmune cases), the small fibers can slowly regrow, leading to a reduction in pain symptoms.